#regulatoryconsulting

[ddregpharma]

Submission deadline approaching with an incomplete dossier? Don't let manual research slow you down.

VITALIC RegIntel helps regulatory teams submit faster by: ✔ Instantly identifying dossier gaps. ✔ Finding reliance pathways across 100+ global health authorities. ✔ Using historical authority queries to reduce submission errors and avoid costly rework.

Turn deadline pressure into submission readiness with smarter regulatory intelligence.

🔗 Learn more: https://www.ddregpharma.com/products/vitalic-regintel

#RegulatoryAffairs #RegulatoryCompliance #RegulatoryIntelligence #DossierPreparation #SubmissionDeadline #PharmaCompliance #VitalicRegIntel #DrugRegistration #PharmaTech #DDReg

[ddregpharma]

Safety Data Exchange Agreements: The PV Obligation No Licensing Deal Gets Right 

Safety Data Exchange Agreements are operational pharmacovigilance documents that must be treated with the same rigour applied to the submission of a clinical safety data package. A licensing deal that fails to establish a clear, jurisdiction-specific, operationally detailed SDEA does not transfer pharmacovigilance risk, it multiplies it. Regulatory authorities across the EU, US, UK, and Japan have demonstrated repeatedly that they expect MAHs to have documented, functional safety data exchange systems in place. The cost of failure is measured in inspection findings, regulatory action, and, ultimately, patient safety. 

DDReg’s pharmacovigilance team supports pharmaceutical and biotechnology companies in drafting, reviewing, and operationalising Safety Data Exchange Agreements across global licensing, co-development, and co-promotion arrangements. From global safety database architecture and QPPV interface planning to jurisdiction-specific ICSR reporting provisions and audit programme design, DDReg provides expert support that ensures PV agreements are both regulatorily compliant and operationally functional across all licensed territories.  Read More:- Click here

[traccglobal23]

Best FDA 510K Consultants for Medical Devices

FDA 510K Consultants offer comprehensive regulatory solutions for medical device companies seeking FDA clearance in the U.S. market. The FDA 510(k) submission process involves demonstrating that a new medical device is substantially equivalent to a legally marketed predicate device. Consultants assist manufacturers in preparing accurate technical files, conducting gap assessments, managing product testing, reviewing labeling requirements, and compiling all necessary documents for submission. They also help ensure compliance with FDA Quality System Regulations and applicable international standards. With expert FDA 510K consulting support, companies can simplify the complex regulatory pathway, reduce submission errors, shorten approval timelines, and successfully launch their medical devices in the competitive U.S. healthcare industry.

[ddregpharma]

Advanced Toxicology Strategy in Drug & Device Development

Learn how a proactive toxicology strategy in drug and device development ensures safety & regulatory compliance.

[ddregpharma]

𝐖𝐡𝐚𝐭 𝐝𝐨 𝟏𝟎 𝐩𝐫𝐢𝐧𝐜𝐢𝐩𝐥𝐞𝐬 𝐦𝐞𝐚𝐧 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐩𝐡𝐚𝐫𝐦𝐚? The FDA & EMA have released their 𝐉𝐨𝐢𝐧𝐭 𝐀𝐈 𝐆𝐮𝐢𝐝𝐢𝐧𝐠 𝐏𝐫𝐢𝐧𝐜𝐢𝐩𝐥𝐞𝐬 𝟐𝟎𝟐𝟔, a global framework reshaping how medicines are discovered, tested, and approved. Discover how AI is transforming clinical trials, submissions & beyond. 👇 Read here: https://tinyurl.com/4b955srb

[ddregpharma]

EU GMP Annex Updates 2026 | Annex 11 Revision, Nitrosamines & ATMP GMP Changes

Explore EU GMP Annex updates 2026, including nitrosamine risk expectations, Annex 11 revision, and changes shaping EMA inspections.

[ddregpharma]

FDA QMSR Is Live: New Inspection Regime Explained - DDReg

February 2, 2026, the FDA QMSR is in effect. Learn how the transition of QSR to ISO 13485 impacts medical device inspections, risk managemen

[ddregpharma]

Inspection Findings Related to Vendor Oversight in Pharmacovigilance

Learn how vendor oversight in pharmacovigilance ensures regulatory compliance and protects patient safety.